Clinical trial end points for high-grade glioma: The evolving landscape

The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA.
Neuro-Oncology (Impact Factor: 5.56). 03/2011; 13(3):353-61. DOI: 10.1093/neuonc/noq203
Source: PubMed


To review the strengths and weaknesses of primary and auxiliary end points for clinical trials among patients with high-grade glioma (HGG). Recent advances in outcome for patients with newly diagnosed and recurrent HGG, coupled with the development of multiple promising therapeutics with myriad antitumor actions, have led to significant growth in the number of clinical trials for patients with HGG. Appropriate clinical trial design and the incorporation of optimal end points are imperative to efficiently and effectively evaluate such agents and continue to advance outcome. Growing recognition of limitations weakening the reliability of traditional clinical trial primary end points has generated increasing uncertainty of how best to evaluate promising therapeutics for patients with HGG. The phenomena of pseudoprogression and pseudoresponse have made imaging-based end points, including overall radiographic response and progression-free survival, problematic. Although overall survival is considered the "gold-standard" end point, recently identified active salvage therapies such as bevacizumab may diminish the association between presalvage therapy and overall survival. Finally, advances in imaging as well as the assessment of patient function and well being have strengthened interest in auxiliary end points assessing these aspects of patient care and outcome. Better appreciation of the strengths and limitations of primary end points will lead to more effective clinical trial strategies. Technical advances in imaging as well as improved survival for patients with HGG support the further development of auxiliary end points evaluating novel imaging approaches as well as measures of patient function and well being.

Download full-text


Available from: Minesh P Mehta, Oct 01, 2015
16 Reads
  • Source
    • "Recent publications propose measurements of tumor lesions by volume and area calculations considering the irregular geometry of the injury [1] [3]. Nevertheless the procedure standardized through the volumes doesn't exist. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently in the biomedical field of image processing software are used for quantitative measurement of tumor lesions, but the analysis of longitudinal studies has limitations; mainly for monitoring of treatment effect and some of this software are owners. Existing software from brain tumor diagnosis and evaluation treatment is a manual process of mensuration of the size of the tumor and alone slide measurement selected, without one a tool that integrates all the functionalities for the quantitative evaluation of the lesions and applied treatments. This justifies finding new and validated tools for imaging biomarkers (IB) applied to magnetic resonance image (MRI). A series of 29 pediatric patients, 14 females and 15 males, between 3 to 18 years, with confirmed malignant brain tumors and treated with a monoclonal antibody nimotuzumab, were evaluated during 2 years for to validate IB-MRI. The MRI were obtained with a 1.5 T MR Symphony Maestro Class System (Siemens, Germany). The protocol included weighted images in T2, T1 and FLAIR. A tool developed in Matlab was obtained. Segmentation and reconstruction methods in three dimensions (3D) were applied and were also integrated in a single interface to integrate others separate tools. Additionally includes the use of an automated method of segmentation of background noise that reduces the amount of points to be processed. The volumes calculated overlap each technique reflecting different biological realities. Our tool is effective to quantitatively evaluate the antitumor effect to treatment.
    Symposium of Image, Signal Processing, and Artificial Vision (STSIVA), 2013 XVIII, Bogotá, Colombia; 09/2013
  • Source
    • "Malignant glioma is the most common primary brain tumor with high migration and invasion [1]. Chemotherapy is one of the most feasible therapeutic modalities for the patients who suffered from glioma invasion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitogen-activated protein kinases/Extracellular signal-regulated kinase (MAPK/ERK) pathway is essential for migration and invasion of malignant glioma. It is efficient to inhibit migration and invasion of glioma cells by targeting this pathway. Oleanolic acid (OA) has been well demonstrated to suppress survival, growth and angiogenesis of glioma cells. However, it is still unknown if OA affects the migration and invasion of glioma cells. We utilized U-87 MG glioma cell lines and primary glioma cells from patients to study the effect of OA on migration and invasion of glioma cells with multidisciplinary approaches. In this study, we found that OA significantly decreased the ability of glioma cells to migrate and invade. Epithelial-mesenchymal transition (EMT) of glioma cells was also suppressed by OA treatment. Furthermore, MAPK/ERK pathway was greatly inhibited in glioma cells under OA treatment. MAPK/ERK reactivation induced by a recombinant lentiviral vector, Lv-MEK, was able to rescue the inhibitory effect of OA on migration and invasion of glioma cells. Taken together, we provided evidences that OA was a MAPK/ERK pathway-targeting anti-tumor agent. Although the concentrations we used exceeded its physiological level, OA may be used to prevent migration and invasion of glioma cells by developing its derivatives with enhanced bioactivity.
    PLoS ONE 08/2013; 8(8):e72079. DOI:10.1371/journal.pone.0072079 · 3.23 Impact Factor
  • Source
    • "Important measures of treatment efficacy in phase 2 and 3 trials of patients with glioblastoma include OS, radiographic response, and duration of tumor control (ie, progression-free survival [PFS]) [5, 6]. Although OS is considered the gold standard clinical end point, it does not directly measure the impact of a specific regimen because of the confounding effects of salvage therapy and other variables. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since 1990, the primary criteria used for assessing response to therapy in high-grade gliomas were those developed by Macdonald and colleagues, which incorporated 2-dimensional area measurements of contrast-enhancing tumor regions, corticosteroid dosing, and clinical assessment to arrive at a designation of response, stable disease, or progression. Recent advances in imaging technology and targeted therapeutics, however, have exposed limitations of the Macdonald criteria and have highlighted the need for reevaluation of response assessment criteria. In 2010, the Response Assessment in Neuro-Oncology (RANO) Working Group published updated criteria to address this need and to standardize response assessment for high-grade gliomas. In 2009, prior to the publication of the RANO criteria, the randomized, placebo-controlled, multicenter, phase 3 AVAglio trial was designed and initiated to investigate the effectiveness of radiotherapy and temozolomide with or without bevacizumab in newly diagnosed glioblastoma. The AVAglio protocol enacted specific measures to adapt the Macdonald criteria to the frontline treatment setting and to antiangiogenic agent evaluation, including the incorporation of a T2/fluid-attenuated inversion recovery component, qualitative assessment of irregularly shaped contrast-enhancing lesions, and a decision tree for confirming or ruling out pseudoprogression. Moreover, the protocol outlines practical means by which these adapted response criteria can be implemented in the clinic. This article describes the evolution of radiographic response criteria for high-grade gliomas and highlights the similarities and differences between those implemented in the AVAglio study and those subsequently published by RANO.
    Current Neurology and Neuroscience Reports 05/2013; 13(5):347. DOI:10.1007/s11910-013-0347-2 · 3.06 Impact Factor
Show more